Outcome in intermediate or high risk prostate cancer patients receiving radiation dose and hormone therapy

By Karlsdottir Asa   Muren Ludvig Paul   Wentzel-Larsen Tore   Johannessen Dag   Haukaas Svein Andreas   Halvorsen Ole Johan   Dahl Olav  

Acta Oncologica, Vol. 48, Iss. 6, 2009-08 ,pp. : 874-881

Informa Healthcare

Access to resources Recommend Favorite

Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT)

By Cho D.   Di Blasio C.J.   Rhee A.C.   Kattan M.W.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 4, 2003-07 ,pp. : 282-291

Elsevier

Access to resources Recommend Favorite

Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: The effect of bisphosphonate therapy on bone scintigraphy results

By Roudier M.P.   Vesselle H.   True L.D.   Higano C.S.   Ott S.M.   King S.H.   Vessella R.L.  

Clinical and Experimental Metastasis, Vol. 20, Iss. 2, 2003-03 ,pp. : 171-180

Springer Publishing Company

Access to resources Recommend Favorite

The timing of hormone therapy for men with asymptomatic advanced prostate cancer

By Messing E.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 4, 2003-07 ,pp. : 245-254

Elsevier

Access to resources Recommend Favorite

Hormone Resistance in Prostate Cancer

By Pilat M.J.P.  

Cancer and Metastasis Reviews, Vol. 17, Iss. 4, 1998-01 ,pp. : 373-381

Springer Publishing Company

Access to resources Recommend Favorite